Back to News
Oct 30, 2025 12:30 PM

Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook

Merck & Co., Inc. (NYSE:MRK) stock traded in a volatile session on Thursday following its third-quarter earnings report and updated fiscal 2025 outlook.

The pharma giant reported adjusted earnings per share of $2.58, surpassing consensus estimates of $2.35, a jump from $1.57 reported a year ago.

Merck reported sales of $17.28 billion, a 4% increase year-over-year, and exceeded the analysts’ projections of $16.96 billion.

Also Read: Merck’s New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

Segment And Drug Performance

The pharmaceutical segment recorded $15.61 billion in sales, up 4% year over year, driven by growth in oncology, cardiovascular, and diabetes, partially offset ...